Novartis AG won U.S. approval for the first in a new line of psoriasis drugs that aim to better treat the itchy, sometimes debilitating skin condition.
The Food and Drug Administration cleared the treatment to be called Cosentyx. The medicine, also known as secukinumab, is predicted to top $1 billion in sales by 2020 and will compete with other biologic drugs including AbbVie Inc.'s No. 1 seller, Humira, and Amgen Inc.'s best-selling Enbrel. The therapy was backed in November by European Commission health regulators.
About 7.5 million Americans have psoriasis, which is an autoimmune disease that can cause raised, red ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.